Abstract
Obesity, classified by the American Medical Association in 2013 as a disease, is an epidemic that is drawing serious global attention. It is the most common preventable disease and the most common modifiable risk factor for several chronic diseases. It is an independent cause of increased morbidity and mortality. Obesity is spreading across most countries, socio-economic strata, age groups, gender groups, and races, albeit to variable degrees. It is concerning that both adults and children are increasingly afflicted by obesity. Both incidence and prevalence of the disease are on the rise. The direct and indirect costs attributable to obesity have reached billions of US dollars. Obesity management involves a multi-disciplinary approach that includes the patient and his or her family, the primary care provider, a dietician or nutrition specialist and physical trainer. It may also require specialist care in the use of pharmacological and surgical interventions. Currently available anti-obesity drugs are indicated for those who are obese (BMI of 30 kg/m2) or overweight (BMI of 27 kg/m2) with at least one weight-related comorbid condition. This article focuses on the FDA-approved antiobesity drugs, their mechanisms of action, chemical structures, efficacy, safety profiles and known side effects.
Keywords: Body mass index, diet, drugs, exercise, lifestyle modification, lorcaserin, obesity, orlistat, phenteramine, pharmacotherapy.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Contemporary Review of Drugs Used to Treat Obesity
Volume: 11 Issue: 4
Author(s): Bhargavi Patham, Debabrata Mukherjee and Zinnia T. San Juan
Affiliation:
Keywords: Body mass index, diet, drugs, exercise, lifestyle modification, lorcaserin, obesity, orlistat, phenteramine, pharmacotherapy.
Abstract: Obesity, classified by the American Medical Association in 2013 as a disease, is an epidemic that is drawing serious global attention. It is the most common preventable disease and the most common modifiable risk factor for several chronic diseases. It is an independent cause of increased morbidity and mortality. Obesity is spreading across most countries, socio-economic strata, age groups, gender groups, and races, albeit to variable degrees. It is concerning that both adults and children are increasingly afflicted by obesity. Both incidence and prevalence of the disease are on the rise. The direct and indirect costs attributable to obesity have reached billions of US dollars. Obesity management involves a multi-disciplinary approach that includes the patient and his or her family, the primary care provider, a dietician or nutrition specialist and physical trainer. It may also require specialist care in the use of pharmacological and surgical interventions. Currently available anti-obesity drugs are indicated for those who are obese (BMI of 30 kg/m2) or overweight (BMI of 27 kg/m2) with at least one weight-related comorbid condition. This article focuses on the FDA-approved antiobesity drugs, their mechanisms of action, chemical structures, efficacy, safety profiles and known side effects.
Export Options
About this article
Cite this article as:
Patham Bhargavi, Mukherjee Debabrata and Juan T. San Zinnia, Contemporary Review of Drugs Used to Treat Obesity, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (4) . https://dx.doi.org/10.2174/1871525712666140317162655
DOI https://dx.doi.org/10.2174/1871525712666140317162655 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of Mitochondrial Toxicity of HIV-1 Antiretroviral Drugs on Lipodystrophy and Metabolic Dysregulation
Current Pharmaceutical Design Ascorbic Acid: Its Role in Immune System and Chronic Inflammation Diseases
Mini-Reviews in Medicinal Chemistry How to Recognize Epicardial Origin of Ventricular Tachycardias?
Current Cardiology Reviews Development of Gene Therapies for Cardiovascular and Renal Diseases by Nucleic Acid Medicines
Medicinal Chemistry Human Heart Cardiomyocytes in Drug Discovery and Research: New Opportunities in Translational Sciences
Current Pharmaceutical Biotechnology Carotid Intima Media Thickness and Beyond
Current Drug Targets - Cardiovascular & Hematological Disorders Bio Molecular Considerations in Major Depression and Ischemic Cardiovascular Disease
Central Nervous System Agents in Medicinal Chemistry Recent Developments in the Synthesis of Acetylcholinesterase Inhibitors
Mini-Reviews in Medicinal Chemistry Graphical Abstracts
Letters in Drug Design & Discovery Mediterranean Diet Rich in Olive Oil and Obesity, Metabolic Syndrome and Diabetes Mellitus
Current Pharmaceutical Design Models to Study Atherosclerosis: A Mechanistic Insight
Current Vascular Pharmacology Trypanocidal Activity of Nitroaromatic Prodrugs: Current Treatments and Future Perspectives
Current Topics in Medicinal Chemistry Emergence of Lipid-Based Vesicular Carriers as Nanoscale Pharmacotherapy in Rheumatoid Arthritis
Recent Patents on Nanomedicine Role of Oxidative Stress and Mitochondrial Dysfunction in Skeletal Muscle in Type 2 Diabetic Patients
Current Pharmaceutical Design Foreword: The Year in Review: Comments on Plants, Cyclodextrins, Microbiota, and Diabetes
Current Pharmaceutical Design Novel Antidepressant Drugs, Arterial Hypertension and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Vitamin D Deficiency: Universal Risk Factor for Multifactorial Diseases?
Current Drug Targets Nitric Oxide and Dietary Factors: Part IV Traditional Japanese Food (Soy Products, Fish and Tea)
Vascular Disease Prevention (Discontinued) Calcium Channel Blockers in the Management of Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial [Hot topic: Polyunsaturated Fatty Acids and Human Health: A Critical Appraisal of the Evidence (Executive Editor: Antonio Cherubini)]
Current Pharmaceutical Design